| Gender |
|
| Women n (%) |
594 (58.9%) |
| Men n (%) |
415 (41.1%) |
| Race n (%) |
|
| White |
789 (78.2%) |
| Asian |
108 (10.7%) |
| Black |
74 (7.3%) |
| Other/Multiple |
38 (3.7%) |
| Ethnicity n (%) |
|
| Non-Hispanic |
980 (97.1%) |
| Hispanic |
29 (2.9%) |
| Smoking status n (%) |
|
| Current smoker |
240 (23.8%) |
| Former smoker |
529 (52.5%) |
| Never smoker |
238 (23.6%) |
| Pack-years smoking |
|
| Median (range) |
30 (0-240) |
| Stage at tumor analyses n (%) |
|
| I |
47 (4.7%) |
| II |
67 (6.7%) |
| III |
145 (14.4%) |
| recurrent |
61 (6.1%) |
| IV |
687 (68.2%) |
| Histology n (%) |
|
| Adenocarcinoma |
899 (89.1%) |
| NSCLC (NOS) |
55 (5.5%) |
| Squamous cell carcinoma |
38 (3.8%) |
| Other |
17 (1.7%) |
| Type of tissue n (%) |
|
| Surgical specimen |
359 (35.6%) |
| Small biopsy |
264 (26.2%) |
| Cytology block from aspirate/fluid |
385 (38.2%) |
| Anatomic site of tissue acquisition n (%) |
|
| Lung |
445 (44.1%) |
| Mediastinal/hilar lymph node |
224 (22.2%) |
| Pleura |
132 (13.1%) |
| Soft tissue/bone |
57 (5.6%) |
| Brain |
53 (5.3%) |
| Liver |
31 (3.1%) |
| Extra-thoracic lymph node |
29 (2.9%) |
| Adrenal |
8 (0.8%) |
| Other |
30 (3.0%) |
| Tumor biomarker testing n (%, from total cases) |
|
| EGFR mutation (exons 18-21) |
1009 (100%) |
| ALK rearrangement (FISH, IHC or NGS) |
895 (88.7%) |
| ROS1 rearrangement (FISH, IHC or NGS) |
537 (53.2%) |
| KRAS mutation |
841 (83.3%) |
| BRAF mutation |
143 (14.2%) |
| ERBB2 mutation |
144 (14.3%) |
| NGS-based testing/other technology |
179 (17.7%) |
